SCHEMBL26601673

SCHEMBL26601673

CC(C)(C)c1ccc(Br)c(OCCO[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
MAPK1 P28482 2/20 0.40
KDM4E B2RXH2 5/20 0.38
SMN1; SMN2 Q16637 5/20 0.37
TSHR P16473 2/20 0.37
LMNA P02545 2/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
ALDH1A1 P00352 4/20 0.35
KMT2A Q03164 3/20 0.35
POLB P06746 1/20 0.35
DUT P33316 2/20 0.34
RECQL P46063 1/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19000481 0.84 L3MBTL1 (0.44) MAPTNPSR1MAPK1KDM4ESMN1; SMN2
SCHEMBL19284924 0.83 S1PR4 (0.41) MAPTKDM4ESMN1; SMN2LMNAALDH1A1
SCHEMBL30326208 0.83 GAA (0.36) MAPTMAPK1KDM4ETSHRALDH1A1
SCHEMBL28756202 0.83 MAPT (0.43) MAPTNPSR1MAPK1KDM4ESMN1; SMN2
SCHEMBL12134818 0.83 FFAR1 (0.39) MAPTKDM4ESMN1; SMN2LMNADUT
SCHEMBL815507 0.81 KDM4E (0.46) MAPTNPSR1MAPK1KDM4ESMN1; SMN2
SCHEMBL814500 0.81 KDM4E (0.47) MAPTNPSR1MAPK1KDM4ESMN1; SMN2
SCHEMBL26601729 0.80 SLC6A4 (0.47) MAPTNPSR1MAPK1KDM4ESMN1; SMN2
SCHEMBL1927440 0.79 HTR7 (0.50) MAPTMAPK1KDM4ESMN1; SMN2LMNA
SCHEMBL24325188 0.78 LMNA (0.35) MAPTNPSR1MAPK1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
EP-4511117-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN1B, CLIC1, HCN1 MAPT 4228/4885NPSR1 579/4885MAPK1 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.